Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China
Authors
Keywords
-
Journal
JOURNAL OF MEDICAL ECONOMICS
Volume -, Issue -, Pages 1-9
Publisher
Informa UK Limited
Online
2018-08-23
DOI
10.1080/13696998.2018.1515769
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments
- (2017) S. De Groot et al. PLoS One
- Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015
- (2017) et al. JAMA Oncology
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) B. Escudier et al. ANNALS OF ONCOLOGY
- Cost-Effectiveness Analysis of Using Everolimus or Axitinib in Patients with Metastatic Renal Cell Carcinoma WHO Have Failed to Use of Pazopanib or Sunitinib in First-Line Treatment
- (2016) ME Romero Prada et al. VALUE IN HEALTH
- Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4)
- (2015) R. J. Motzer et al. ANNALS OF ONCOLOGY
- An Indirect Comparison of Everolimus Versus Axitinib in US Patients With Advanced Renal Cell Carcinoma in Whom Prior Sunitinib Therapy Failed
- (2015) Steven Sherman et al. CLINICAL THERAPEUTICS
- SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer
- (2015) Christian Eichelberg et al. EUROPEAN UROLOGY
- Cost-effectiveness analysis of axitinib through a probabilistic decision model
- (2015) Panagiotis Petrou EXPERT OPINION ON PHARMACOTHERAPY
- Kidney Cancer, Version 3.2015
- (2015) Robert J. Motzer et al. Journal of the National Comprehensive Cancer Network
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma
- (2014) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial
- (2014) Robert J Motzer et al. LANCET ONCOLOGY
- A Cost Effectivness Analysis of Everolimus Compared with Axitinib in the Treatment of Metastatic Renal Cell Carcinoma in the United Kingdom
- (2014) D. Chandiwana et al. VALUE IN HEALTH
- Relationship Between Progression-Free Survival (Pfs) and Overall Survival (OS) in Hormone Receptor-Negative Metastatic Breast Cancer (Mbc): A Comparative Effectiveness Analysis Using Linked Claims, Emr, and Mortality Records
- (2014) V.F. Schabert et al. VALUE IN HEALTH
- Critical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinoma
- (2014) Ding-Wei Ye et al. OncoTargets and Therapy
- Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial
- (2013) G. Procopio et al. ANNALS OF ONCOLOGY
- Cost analysis of S1 and XELOX as adjuvant therapy for gastric cancer
- (2013) Jianping He et al. ANTI-CANCER DRUGS
- Everolimus: side effect profile and management of toxicities in breast cancer
- (2013) Elisavet Paplomata et al. BREAST CANCER RESEARCH AND TREATMENT
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial
- (2013) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
- (2013) Thomas E Hutson et al. LANCET ONCOLOGY
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Economic Evaluation of First-Line Adjuvant Chemotherapies for Resectable Gastric Cancer Patients in China
- (2013) Chongqing Tan et al. PLoS One
- A Cost-Effectiveness Analysis of Axitinib and Sorafenib for 2nd Line Treatment of Advanced Renal Cell Carcinoma After Failure of Cytokines in the United States
- (2013) I.O. Stillman et al. VALUE IN HEALTH
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
- (2012) Patricia Guyot et al. BMC Medical Research Methodology
- Economic Evaluation of First-Line Treatments for Metastatic Renal Cell Carcinoma: A Cost-Effectiveness Analysis in A Health Resource–Limited Setting
- (2012) Bin Wu et al. PLoS One
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cost-Effectiveness of Adding Rh-Endostatin to First-Line Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer in China
- (2011) Bin Wu et al. CLINICAL THERAPEUTICS
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started